# Effect of Lipid Modifying Drugs on HDL Function in Patients With Hyperlipidemia

> **NCT02942602** · NA · COMPLETED · sponsor: **Yonsei University** · enrollment: 58 (actual)

## Conditions studied

- Hyperlipidemia

## Interventions

- **DRUG:** Atorvastatin 20 mg
- **DRUG:** Cholestyramine 8 g
- **DRUG:** Omega-3 2g
- **DRUG:** Concurrent with Atorvastatin 5 mg + Ezetimibe 10 mg
- **BEHAVIORAL:** Lifestyle modification

## Key facts

- **NCT ID:** NCT02942602
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-03
- **Primary completion:** 2016-05-23
- **Final completion:** 2016-05-23
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2018-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02942602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02942602, "Effect of Lipid Modifying Drugs on HDL Function in Patients With Hyperlipidemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02942602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*